クオイン・ファーマシューティカルズ
Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -1.77 | $0 | -$5M |
| 2025 Q4 | -2.92 | $0 | -$5M |
| 2025 Q3 | -6.71 | $0 | -$2M |
| 2025 Q2 | -6.28 | $0 | -$4M |
| 2025 Q1 | -6.50 | $0 | -$3M |
| 2024 Q4 | -12.37 | $0 | -$2M |
| 2024 Q3 |
| -16.45 |
| $0 |
| -$2M |
| 2024 Q2 | -0.39 | $0 | -$2M |